We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byFay Perkins
Modified over 4 years ago
CHARM Program: 3 Component trials comparing candesartan with placebo
CHARM Program: Baseline characteristics
CHARM Program: Baseline medications
CHARM-Overall: CV death and non-CV death
CHARM Program: Reduction in mortality and morbidity
CHARM Program: Reduction in CHF hospitalization
CHARM-Preserved: Hospital admissions for CHF
CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis
CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis (cont’d)
CHARM-Added: Effect of combined ACE inhibitor/ -blocker/AT1-receptor blocker
CHARM-Overall: Drug discontinuations for adverse events
CHARM: Clinical implications
CHARM-Overall: Reduction in new-onset diabetes
CHARM: Impact of treatment
HF with preserved LV systolic function in the elderly: Impact on survival
CHARM-Preserved: CV death or CHF hospitalization
CHARM-Preserved: Primary and secondary outcomes
CHARM-Preserved: Clinical implications
VALIANT: Concomitant medications
VALIANT: Treatments show similar effect on outcome
VALIANT: Clinical implications
VALIANT: Effect of treatment on mortality—Subgroup analysis
RESOLVD: Comparative impact of ACE inhibitor, ARB, and -blocker alone or combined on LVEF
Differences in dosing among ARB trials
Survival studies of -blockade in HF
-Blockers improve survival in diabetic patients with HF: A meta-analysis
MERIT-HF: -Blockade improves survival in CHF
MERIT-HF: -Blockade improves survival in post-MI patients with HF
MERIT-HF: Subgroup analysis in post-MI patients with HF (LVEF <25%)
SOLVD: Heart rate predicts progression of asymptomatic LV dysfunction
MERIT-HF: Effect of -blockade on heart rate
MERIT-HF: -Blockade decreases mortality and hospitalization independent of resting heart rate
CHRISTMAS: Trial profile
CHRISTMAS: Change in LVEF according to number of segments affected by myocardial hibernation
COMET: Trial profile
COMET: All-cause mortality
COMET: Heart rate at each visit
COMET: Blood pressure
-Blocker HF trials: Mortality results
Mortality rates in perspective CIBIS-II, MERIT-HF, COMET
Immediate-release vs sustained release metoprolol: Significant pharmacokinetic differences
COMET: Clinical implications
Comparison of -blocker effects in major HF trials
Not all -blockers are the same
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)
McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
Purpose To determine whether metoprolol controlled/extended release
Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.
MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
analysis from the SHIFT study
A randomised, double-blind, placebo-controlled phase III study
SOLVD (Studies of Left Ventricular Dysfunction)
HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
Update on -Blockers In the Management of Heart Failure.
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
© 2019 SlidePlayer.com Inc. All rights reserved.